Clinical Assistant Professor
Undergraduate: Indiana University
Medical School: Indiana University School of Medicine
Residency: Ball Memorial Hospital
Fellowship: Medical College of Ohio
Board Certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine
Clinical Services
Research Interests
- Creating new breast cancer and lung cancer treatment protocols
- The role of the PET scan in predicting lung cancer response
- Novel metronomic chemotherapy approaches for the management of agressive estrogen negative, progesterone negative, and Her-2/neu negative breast cancer
- Novel pulsed chemotherapy approaches in the treatment of lung cancer
Selected Publications
Quan WD Jr, Milligan KS, Quan FM, Cuenca RE, Khan N, Liles DK, Walker PR. Continuous infusion interleukin-2 and intravenous famotidine in metastatic melanoma. Cancer Biother Radiopharm. 2006 Dec;21(6):607-12.
Quan WD Jr, Walker PR, Quan FM, Ramirez M, Elsamaloty HM, Ghai V, Vinogradov M, Liles DK. Activity of continuous infusion plus pulse interleukin-2 with famotidine in patients with metastatic kidney cancer or melanoma previously treated with interleukin-2. Cancer Biother Radiopharm. 2006 Oct;21(5):437-42.
Walker PR, Khuder SA, Quan WD Jr. Continuous infusion interleukin-2 and antihistamines in metastatic kidney cancer. Cancer Biother Radiopharm. 2005 Oct;20(5):487-90.
Quan WD Jr, Khan N, Ramirez M, Taylor WC, Quan F, Vinogradov M, Walker P. Correlation between development of pulmonary edema and response of pulmonary metastases of metastatic melanoma and kidney cancer to high-dose continuous-infusion interleukin-2. Cancer Biother Radiopharm. 2005 Apr;20(2):151-4.
Quan W Jr, Ramirez M, Taylor C, Quan F, Vinogradov M, Walker P. Administration of high-dose continuous infusion interleukin-2 to patients age 70 or over. Cancer Biother Radiopharm. 2005 Feb;20(1):11-5.
Vaena DA, Walker P, Pennington K, Stephens A, Stender MJ, Yiannoutsos CT,Young C, Stoner C, Cripe LD; Hoosier Oncology Group. Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. Leuk Res. 2004 Jan;28(1):49-52.
Skeel RT, Huang J, Manola J, Wilding G, Dreicer R, Walker P, Muggia F, Crawford ED, Dutcher JP, Loehrer PJ. A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest. 2003;21(1):41-6.
Sonpavde G, Ansari R, Walker P, Sciortino DF, Gabrys GT, Murdock A, Gonin R, Einhorn LH. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: a Hoosier Oncology Group Trial. Am J Clin Oncol. 2000 Feb;23(1):68-70.
Quan WD Jr, Casal R, Rosenfeld M, Walker PR.
Alpha interferon-2b, leucovorin, and 5-fluorouracil (ALF) in non-small cell lung cancer. Cancer Biother Radiopharm. 1996 Aug;11(4):229-34.
Walker PR. Actions speak louder than words.
J Clin Oncol. 1994 Dec;12(12):2769-70.
